Biotech firms GeoVax and Novavax announce strategic updates

Biotechnology companies GeoVax Labs and Novavax have provided updates regarding their corporate strategies and market positions.

GeoVax Labs has scheduled a hearing with the Nasdaq Hearings Panel for October 13, 2026, to appeal a delisting determination. The appeal concerns the company’s failure to meet minimum bid price requirements. GeoVax intends to present a plan to regain compliance while continuing to advance its GEO-MVA clinical program and seeking strategic partners.

Novavax is shifting its business model toward licensing its Matrix-M adjuvant platform to larger pharmaceutical companies. CEO John Jacobs stated the company has reduced its expense base by 80% to 90% over the last three years and maintains a cash runway of over two years. The company currently works with four of the world’s ten largest pharmaceutical firms, including Sanofi and Pfizer, across various infectious disease and oncology research areas.